A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis

Arthritis and Rheumatology

Volumn 67, Issue 2, 2015, Pages 334-343

  Fleischmann, Roy M ^a   Damjanov, Nemanja S ^b   Kivitz, Alan J ^c   Legedza, Anna ^d   Hoock, Thomas ^d   Kinnman, Nils ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Altoona Center for Clinical Research   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; C REACTIVE PROTEIN; DECERNOTINIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; 2-((2-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)PYRIMIDIN-4-YL)AMINO)-2-METHYL-N-(2,2,2-TRIFLUOROETHYL)BUTANAMIDE; ANTIRHEUMATIC AGENT; ENZYME INHIBITOR; FUSED HETEROCYCLIC RINGS; JANUS KINASE 3; VALINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASSESSMENT OF HUMANS; BRONCHITIS; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; INFECTION RISK; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OSTEOMYELITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DISABILITY; DOSE RESPONSE; ENZYMOLOGY; LIVER; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; QUESTIONNAIRE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ALANINE TRANSAMINASE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; JANUS KINASE 3; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; TREATMENT OUTCOME; VALINE;

EID: 84922808076     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38949     Document Type: Article

References (30)

1. Keystone E, Smolen J, van Riel PL,. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 Suppl 5: v48-54.
2. Rindfleisch JA, Muller D,. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005; 72: 1037-47.
3. Strand V, Singh JA,. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2008; 14: 234-54.
4. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
5. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
6. Tanaka Y, Maeshima Y, Yamaoka K,. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012; 71 Suppl 2: i70-4.
7. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.
8. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60.
9. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 617-29.
10. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
11. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
12. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo [published erratum appears in Arthritis Rheum 2012;64:1487]. Arthritis Rheum 2009; 60: 1895-905.
13. Ghoreschi K, Laurence A, O'Shea JJ,. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-87.
14. Kyttaris VC,. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012; 6: 245-50.
15. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ,. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223: 132-42.
16. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A,. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72 Suppl 2: ii111-5.
17. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006; 65: 1558-64.
18. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006; 65: 149-56.
19. Thomas R, Lipsky PE,. Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis [review]. Arthritis Rheum 1996; 39: 183-90.
20. Rane SG, Reddy EP,. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994; 9: 2415-23.
21. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O, O'Shea JJ,. The Janus kinases (Jaks). Genome Biol 2004; 5: 253.
22. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995; 270: 797-800.
23. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377: 65-8.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
26. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
27. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
28. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
29. Winthrop KL, Valdez H, Mortensen E, Chew R, Krishnaswami S, Kawabata T, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2012; 64 Suppl: S1051.
30. Ghoreschi K, Laurence A, O'Shea JJ,. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009; 10: 356-60.